For the second year in a row, Portal Instruments presented at the Injectable Drug Delivery Conference in London, UK, which took place on March 24-25, 2015. Organized by Management Forum, this conference showcased established and rising industry leaders, who shed light on the latest self-injection trends, recent changes in the medical device regulatory space, the role connectivity is playing in the injector space, and the interplay of human factors considerations and device requirements.

Among presentations by such companies as Pfizer, Genentech, and Roche, Dr. Patrick Anquetil, Chief Executive Officer of Portal Instruments, spoke of Portal’s needle-free solution to injecting large volumes of viscous biologics in a controllable manner. Portal’s platform is unique in that it transforms the delivery experience and is able to meet and overcome current issues that the incumbent injection devices currently face.

Portal’s novel device addresses some of the top problems of today’s injectors: the need for device connectivity, patient needle-phobia, and a variety of technical challenges. Several companies, including SHL Group and Pfizer, mentioned at the conference that patients are expecting devices to be “intelligent,” “connected,” and “digital.” Patrick noted that “Portal’s device offers patient interactivity, support, education, and compliance features via Bluetooth 4.0 Smartphone connection.” He went on to say that “the device can also be connected to an external computer to alert the patient when to take his/her medicine, for better compliance and improved overall clinical outcomes.”

Learn more about the conference here.

Pages of the Portal Instruments website may contain links to third party websites that are not under the control of Portal Instruments. Portal Instruments is not responsible for the content of any such site and the inclusion of these links does not imply the endorsement of the content of the linked site by Portal Instruments.